Economics of Industry

Ferraro, J., Towse, A., and Mestre-Ferrandiz, J.

Briefing
May 2017

Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required.

Mechanisms designed to encourage companies to undertake R&D on new medicines are generally characterised as either “push” or “pull” programs.

Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.

Seminar Briefing
October 2015

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.

It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas.

On Tuesday 6th October, James Anderson (GSK), Ri De Ridder (RIZIV-INAMI), and Sophia Tickell (Meteosan) will take part in an OHE seminar to discuss the Checklist for Collaborative, Mutually Acceptable Drug Pricing.

A Research Paper on the topic of incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations has just been published by OHE.

It is surprisingly hard to measure how long medical research takes. A recently published study by OHE, Brunel and RAND Europe shows a better way to do that.

Recently published study by OHE, Brunel University, RAND Europe and Kings College London analyses time lags in medical research and where to shorten them.

Dr. Aslam Anis, Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS) in Canada will undertake a short sabbatical with the Office of Health Economics in February 2015.

Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US market may evolve.

Teeling Smith, G. ed.

Monograph
July 1972

This paper is based on a symposium held at the Imperial College of Science and Technology by the Office of Health Economics in 1972.

Pages

Subscribe to RSS - Economics of Industry